trending Market Intelligence /marketintelligence/en/news-insights/trending/OWmnBbr9kz_5wVB-Uivn9Q2 content esgSubNav
In This List

Bristol-Myers Squibb elects 3 independent directors

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bristol-Myers Squibb elects 3 independent directors

Bristol-Myers Squibb Co. said its board elected Michael Bonney, Julia Haller and Phyllis Yale to serve as independent directors.

The appointments are effective at the closing of the New York-based drugmaker's $95 billion acquisition of Celgene Corp. Bonney and Haller are members of Celgene's board.

The addition of the new directors will increase the size of Bristol-Myers' board.

Bonney previously served as CEO and chairman of Kaleido BioSciences Inc. and currently serves as executive chair of the company's board. Haller is the ophthalmologist-in-chief of Wills Eye Hospital in Philadelphia, a position she has held since 2007.

Yale is an advisory partner with Bain & Co.